# POLLUX (NCT02076009)

> A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02076009
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Daratumumab; Lenalidomide; Dexamethasone
- Enrollment: 569
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on POLLUX so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 34
- YouTube: 12
- Podcasts: 9
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=pollux-nct02076009

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02076009", "email": "<work email>"}; the inbox owner confirms by the emailed link.